CAMP4 Therapeutics

#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #Collaboration #GSK #Kidney disease #Neurodegenerative disorders

CAMP4 and GSK advance RNA-based therapeutic discoveries

GSK and CAMP4 Therapeutics have entered into a strategic research, collaboration and license agreement to identify and develop antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications.  “Protein under-expression plays a critical role in diseases such as neurodegenerative and kidney disease. Our collaboration… Read More

#Business & Investment #News

RNA strand
#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #CNS #Genetic diseases #mRNA #RNA #Turning Science into Business

Turning science into business: Amplifying mRNA by targeting regRNAs

DDW’s Diana Spencer speaks to Josh Mandel-Brehm, CEO of Massachusetts-based biotech CAMP4, to understand the role regulatory RNAs play in gene expression and how the founders overcame the challenge of launching a business based on brand new science. DS: CAMP4 leverages research from co-founder Richard Young on how regulatory RNA… Read More

#Business & Investment #Exclusive Content

A strip of 8 PCR tubes on the thermal cycler
#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #Gene mutation #Phase I trial #Rare disease

Potential first-in-class therapeutic for urea cycle disorders enters trial

CAMP4 Therapeutics has dosed the first participant in its Phase I clinical study of CMP-CPS-001, a potential first-in-class therapeutic for the treatment of urea cycle disorders (UCDs). UCDs are a group of rare, severe, inherited metabolic diseases impacting protein metabolism. Mutations in genes encoding urea cycle… Read More

#News